HK1096023A1 - Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 - Google Patents
Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11Info
- Publication number
- HK1096023A1 HK1096023A1 HK07103005.0A HK07103005A HK1096023A1 HK 1096023 A1 HK1096023 A1 HK 1096023A1 HK 07103005 A HK07103005 A HK 07103005A HK 1096023 A1 HK1096023 A1 HK 1096023A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cpt
- azd2171
- human
- combination therapy
- antiangiogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0406446.5A GB0406446D0 (en) | 2004-03-23 | 2004-03-23 | Combination therapy |
PCT/GB2005/001080 WO2005092303A2 (en) | 2004-03-23 | 2005-03-22 | Combination therapy with azd2171 and 5-fu and/or cpt-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1096023A1 true HK1096023A1 (en) | 2007-05-25 |
Family
ID=32188482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07103005.0A HK1096023A1 (en) | 2004-03-23 | 2007-03-20 | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080125447A1 (xx) |
EP (1) | EP1729808B1 (xx) |
JP (1) | JP2007530518A (xx) |
KR (1) | KR20060130763A (xx) |
CN (1) | CN1964742A (xx) |
AT (1) | ATE447974T1 (xx) |
AU (1) | AU2005225193B2 (xx) |
BR (1) | BRPI0508982A (xx) |
CA (1) | CA2610628A1 (xx) |
DE (1) | DE602005017591D1 (xx) |
ES (1) | ES2335292T3 (xx) |
GB (1) | GB0406446D0 (xx) |
HK (1) | HK1096023A1 (xx) |
IL (1) | IL177952A0 (xx) |
MX (1) | MXPA06010758A (xx) |
NO (1) | NO20064755L (xx) |
NZ (1) | NZ549553A (xx) |
WO (1) | WO2005092303A2 (xx) |
ZA (1) | ZA200607555B (xx) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06010755A (es) * | 2004-03-23 | 2006-12-15 | Astrazeneca Ab | Terapia de combinacion. |
GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
CA2614002A1 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
KR20080077678A (ko) * | 2005-12-22 | 2008-08-25 | 아스트라제네카 아베 | Azd2171 및 페메트렉시드의 조합물 |
WO2015082880A1 (en) * | 2013-12-02 | 2015-06-11 | Astrazeneca Ab | Methods of selecting treatment regimens |
WO2020061391A1 (en) * | 2018-09-20 | 2020-03-26 | The Trustees Of Columbia University In The City Of New York | Methods for inhibiting tumor cells using inhibitors of foxo3a antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
CZ303692B6 (cs) * | 1999-02-10 | 2013-03-13 | Astrazeneca Ab | Chinazolinové deriváty jako inhibitory angiogeneze |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
PT2762140T (pt) * | 2001-02-19 | 2017-07-04 | Novartis Ag | Resumo |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
MX2007003506A (es) * | 2004-09-27 | 2007-05-10 | Aztrazeneca Ab | Terapia de combinacion de cancer que comprende azd2171 e imatinib. |
CA2614002A1 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
CA2633211A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
KR20080077678A (ko) * | 2005-12-22 | 2008-08-25 | 아스트라제네카 아베 | Azd2171 및 페메트렉시드의 조합물 |
-
2004
- 2004-03-23 GB GBGB0406446.5A patent/GB0406446D0/en not_active Ceased
-
2005
- 2005-03-22 US US10/594,233 patent/US20080125447A1/en not_active Abandoned
- 2005-03-22 AT AT05729381T patent/ATE447974T1/de not_active IP Right Cessation
- 2005-03-22 CA CA002610628A patent/CA2610628A1/en not_active Abandoned
- 2005-03-22 KR KR1020067021774A patent/KR20060130763A/ko not_active Application Discontinuation
- 2005-03-22 MX MXPA06010758A patent/MXPA06010758A/es active IP Right Grant
- 2005-03-22 ES ES05729381T patent/ES2335292T3/es active Active
- 2005-03-22 NZ NZ549553A patent/NZ549553A/en unknown
- 2005-03-22 AU AU2005225193A patent/AU2005225193B2/en not_active Ceased
- 2005-03-22 WO PCT/GB2005/001080 patent/WO2005092303A2/en active Application Filing
- 2005-03-22 DE DE602005017591T patent/DE602005017591D1/de active Active
- 2005-03-22 JP JP2007504467A patent/JP2007530518A/ja active Pending
- 2005-03-22 BR BRPI0508982-4A patent/BRPI0508982A/pt not_active IP Right Cessation
- 2005-03-22 EP EP05729381A patent/EP1729808B1/en active Active
- 2005-03-22 CN CNA2005800092182A patent/CN1964742A/zh active Pending
-
2006
- 2006-09-07 IL IL177952A patent/IL177952A0/en unknown
- 2006-09-08 ZA ZA200607555A patent/ZA200607555B/en unknown
- 2006-10-20 NO NO20064755A patent/NO20064755L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07103005.0A patent/HK1096023A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2005092303A2 (en) | 2005-10-06 |
EP1729808A2 (en) | 2006-12-13 |
CA2610628A1 (en) | 2005-10-06 |
CN1964742A (zh) | 2007-05-16 |
GB0406446D0 (en) | 2004-04-28 |
ES2335292T3 (es) | 2010-03-24 |
BRPI0508982A (pt) | 2007-08-28 |
AU2005225193B2 (en) | 2008-10-09 |
US20080125447A1 (en) | 2008-05-29 |
ZA200607555B (en) | 2008-05-28 |
NO20064755L (no) | 2006-10-20 |
AU2005225193A1 (en) | 2005-10-06 |
MXPA06010758A (es) | 2006-12-15 |
NZ549553A (en) | 2009-12-24 |
JP2007530518A (ja) | 2007-11-01 |
ATE447974T1 (de) | 2009-11-15 |
WO2005092303A3 (en) | 2006-11-02 |
IL177952A0 (en) | 2007-07-04 |
EP1729808B1 (en) | 2009-11-11 |
KR20060130763A (ko) | 2006-12-19 |
DE602005017591D1 (de) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
ZA200600188B (en) | Combination therapy | |
WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140322 |